Cargando…
Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
Primary splenic angiosarcoma (PSA) is a rare malignancy with poor prognosis. At present, little study is available on immunotherapy in PSA. Here, we report a case of a patient with metastatic PSA who was treated with programmed death-1 (PD-1) inhibitors and vascular endothelial growth factor (VEGF)...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928100/ https://www.ncbi.nlm.nih.gov/pubmed/35311098 http://dx.doi.org/10.3389/fonc.2022.809068 |
_version_ | 1784670581245870080 |
---|---|
author | Xu, Weiran Wang, Kai Gu, Wenguang Nie, Xinxin Zhang, Hao Tang, Chuanhao Lin, Li Liang, Jun |
author_facet | Xu, Weiran Wang, Kai Gu, Wenguang Nie, Xinxin Zhang, Hao Tang, Chuanhao Lin, Li Liang, Jun |
author_sort | Xu, Weiran |
collection | PubMed |
description | Primary splenic angiosarcoma (PSA) is a rare malignancy with poor prognosis. At present, little study is available on immunotherapy in PSA. Here, we report a case of a patient with metastatic PSA who was treated with programmed death-1 (PD-1) inhibitors and vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors combined therapy and achieved complete response (CR). The patient was a 57−year−old woman with three liver metastases. She was treated with seven cycles of toripalimab plus anlotinib. Programmed death-ligand 1 (PD-L1) immunohistochemistry and next-generation sequencing was performed, and the PD-L1 tumor proportion score was 75%. Finally, she achieved CR after six cycles of the combined therapy regimen. No serious adverse events were detected. To the best of our knowledge, this is the first clinical evidence that anti-PD-1 plus anti-VEGF therapy might be a promising option for patients with metastatic PSA. However, more clinical trials are needed to verify this conclusion. |
format | Online Article Text |
id | pubmed-8928100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89281002022-03-18 Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma Xu, Weiran Wang, Kai Gu, Wenguang Nie, Xinxin Zhang, Hao Tang, Chuanhao Lin, Li Liang, Jun Front Oncol Oncology Primary splenic angiosarcoma (PSA) is a rare malignancy with poor prognosis. At present, little study is available on immunotherapy in PSA. Here, we report a case of a patient with metastatic PSA who was treated with programmed death-1 (PD-1) inhibitors and vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors combined therapy and achieved complete response (CR). The patient was a 57−year−old woman with three liver metastases. She was treated with seven cycles of toripalimab plus anlotinib. Programmed death-ligand 1 (PD-L1) immunohistochemistry and next-generation sequencing was performed, and the PD-L1 tumor proportion score was 75%. Finally, she achieved CR after six cycles of the combined therapy regimen. No serious adverse events were detected. To the best of our knowledge, this is the first clinical evidence that anti-PD-1 plus anti-VEGF therapy might be a promising option for patients with metastatic PSA. However, more clinical trials are needed to verify this conclusion. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8928100/ /pubmed/35311098 http://dx.doi.org/10.3389/fonc.2022.809068 Text en Copyright © 2022 Xu, Wang, Gu, Nie, Zhang, Tang, Lin and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xu, Weiran Wang, Kai Gu, Wenguang Nie, Xinxin Zhang, Hao Tang, Chuanhao Lin, Li Liang, Jun Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma |
title | Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma |
title_full | Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma |
title_fullStr | Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma |
title_full_unstemmed | Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma |
title_short | Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma |
title_sort | case report: complete remission with anti−pd−1 and anti−vegf combined therapy of a patient with metastatic primary splenic angiosarcoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928100/ https://www.ncbi.nlm.nih.gov/pubmed/35311098 http://dx.doi.org/10.3389/fonc.2022.809068 |
work_keys_str_mv | AT xuweiran casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma AT wangkai casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma AT guwenguang casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma AT niexinxin casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma AT zhanghao casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma AT tangchuanhao casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma AT linli casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma AT liangjun casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma |